Our primary goal is to advance our proprietary microfluidic liposomal platform through preclinical validation, robust intellectual property protection, and regulatory readiness, establishing a strong foundation for clinical translation.

We are committed to developing technologies that align with oncology practices and hospitals’ needs and priorities by reducing systemic toxicity, improving patient outcomes, and lowering long-term healthcare costs through targeted drug delivery and manufacturing efficiency.

Our Strategies

Technology & R&D Strategy

We prioritise microfluidic precision and reproducibility to optimise liposome size, stability, and drug-loading efficiency, enabling scalable, GMP-compatible manufacturing. Early development focuses on Doxorubicin, with a clear pathway to extend the platform to additional oncology agents.

Regulatory & Compliance Strategy

We adopt a UK-first regulatory approach, aligning early with MHRA expectations through structured preclinical studies, quality systems, and CTA-ready documentation to accelerate progression into clinical trials.

IP & Value Protection Strategy

We build strong, defensible intellectual property covering formulation, process, and microfluidic manufacturing methods to secure long-term competitive advantage and investor protection.

Commercial & Partnership Strategy

We pursue early partnerships with CROs, NHS stakeholders, and pharmaceutical companies to support validation, licensing, and future scale-up while minimising capital intensity.

Capital Efficiency Strategy

Seed funding is deployed in milestone-based stages to maximise value creation, reduce risk, and position the company for follow-on investment or strategic partnerships